“If your nasal polyps get to a phase in which you have a very large and significant polyp load, it’s very hard to get them to go away,” she says. Treatment and Medication Options for Nasal ...
but according to Amgen findings showed treatment with tezepelumab statistically significantly and clinically meaningfully reduced the size of nasal polyps and nasal congestion compared with placebo.
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Participants in the trial were symptomatic despite treatment with standard of care (intranasal corticosteroids [INCS]). Chronic rhinosinusitis with nasal polyps is a condition that can cause ...